A critical population management challenge concerns chronic kidney disease (CKD), which impacts about half of the Medicare population and of diabetics. More than 50% of adults over 30 years of age are likely to develop CKD during their lifetime, and the prevalence of CKD is expected to climb over the next 15 years. Current CKD management is variable and suboptimal, as categorizing the very heterogeneous CKD patient population into risk cohorts for purposes of appropriate treatment is inaccurate. Without accurate risk classification, many patients are over-treated, leading to wasted expenses and adverse events, while others are not identified in time to receive interventions that change the course of the disease. A new algorithm has been created that predicts patients’ risk of renal failure based on a specific set of laboratory tests combined with patient age and gender. Validated by more than 720,000 patients spanning 30 countries, it can reliably predict a patient’s risk of experiencing renal failure requiring dialysis or transplant. Studies show that a lab-based analytics program that incorporates this algorithm with care protocols, dashboards, and educational patient reports can generate substantial savings and improved outcomes for ACOs and health systems.

1. Chronic Kidney Disease
(CKD) Challenges and
New Solutions
PREVALENCE OF CKD ACROSS THE US
CKD MORBIDITY/MORTALITY
Estimated prevalence, CKD, U.S. population, 2015-2030
13.2%
14.4%
16.7%
Current CKD Prevalence for Age >65 yo
44%
SOURCES:
> Hoerger TJ et al., American Journal of Kidney Diseases, March 2015 > Braun LA et al., International Journal of Nephrology and Renovascular Disease 2012:5 151–163 > Centers for Disease Control and Prevention, National Center for Health Statistics. Deaths: Final Date for 2011. www.cdc.gov > U.S. Renal Data System. USROS 2010 Annual Report; 2:219
> 2014 USRDS Annual Data Report; Volume 1 – CKD > Hoerger TJ et al. Am J Kidney Dis. 2015;65(3):403-411, JAMA, SEER Cancer Statistics > United States Renal Data System’s 2010 Annual Data Report and 2011 Annual Data Report. > Braun LA et al., International Journal of Nephrology and Renovascular Disease 2012:5 151–163
> 2013 USRDS Annual Data Report; Volume 2 > 2014 USRDS Annual Data Report; Volume 1 – CKD > Source: U.S. Renal Data System, 2005-2012. http://www.usrds.org/2014/view/v2_02.aspx > Personal communication with Navdeep Tangri, MD, FRCPC; Tangri N et al. JAMA. 2016;315(2):164-174; Lee et al. BMC Health Services Research 2012, 12:252; Viewics analysis
> Personal communication with Navdeep Tangri, MD, FRCPC; Tangri N et al. JAMA. 2016;315(2):164-174; Viewics analysis > JAMA. 2016;315(2):164-174.
Leading cause of death in America9th
mortality rate
in the first year of dialysis
23%
CKD patients’ rate of hospital readmissions40% higher
only to heart disease in
lifetime incidence risk of
morbidity (at age 30 in 2015)
2nd
Heart disease, males* 60.3
Heart disease, females* 55.6
CKD 54.1
Cancer, all sites, males 42.8
Cancer, all sites, both sexes 40.0
Cancer, all sites, females 37.6
HIGH GROWTH RATE
COSTS
SUBOPTIMAL CKD CARE
VIEWICS’ NEW SOLUTION FOR CKD
VIEWICS CKD MANAGEMENT
TM
POTENTIAL COST SAVINGS
The incidence of recognized CKD in people ages 65
and older more than doubled between 2000 and 2008.
Approximate Medicare spending for
End Stage Renal Disease in 2015
$56 billion
$ $$
$$
Approximate Medicare spending per
person for hemodialysis patients in 2015
$98,000
How much more Medicare renal failure
patients cost compared to the average
Medicare population
5x
Patient awareness for those
with Stages 1-3 CKD
Renal failure patients who saw a
nephrologist in the prior year
10%<
33%Amount of dialysis patients who used the
access port associated with the best
outcomes in 2011 (a fistula)
16%
Uses an algorithm that combines laboratory tests, age, and gender to predict a patient’s risk of renal failure
End Stage Renal Disease (ESRD)
Risk Score+ + =Age
Validated as accurate in more than
720,000 patients, 30 countries
Viewics is implementing the predictive analytics application to automatically deliver the
risk score to clinicians and issue customized, educational reports to patients and clinicians.
Approximate full potential savings for U.S.
population of CKD Stage 3 and 4 using
Viewics CKD ManagementTM
To learn more visit www.renalrisk.com
Approximate cost savings per
Stage 4 patient per year using
Viewics CKD ManagementTM
$15B
Incorrect Patient Classification
Viewics CKD ManagementTM
can help
rectify misclassification of Stage 4 CKD
patients into Stage 3 patients due to
inappropriate staging
$5,600
13.2%Estimated prevalence, CKD, U.S. population
2000 2008
Ontario, Canada
will begin requiring the Risk
Score in order to receive
reimbursement for late stage
CKD beginning in April 2016
30%
stage 1
stage 2
stage 3
stage 4
2015
2020
2030